Auditable Cognitive Infrastructure for Neurodegenerative Disease Research
Auditable cognitive infrastructure for neurodegenerative disorders integrating genetics, proteomics, and neuroimaging within the tridimensional framework described in a peer-reviewed publication. Supports comprehensive evidence structuring across 22 neurodegenerative diseases.
Validation Studies
Results reported in our own manuscripts, which have not been peer-reviewed. They describe research cohorts and do not establish clinical performance.
| Analytical Dimension | Empirical Result | Methodological Status & Link |
|---|---|---|
| Causal Pathway Concordance | 5/8 biomarkers validated | Cross-sectional discovery cohort; see preprint |
| Algorithmic Parity | 12/32 spatial & 5/8 causal scores | Web platform matches reference scripts; see unpublished manuscript, not peer-reviewed |
| Taxonomic Range | 22 clinical disorders | Unified ontology spanning AD, FTD, Lewy body, ALS, and prion spectra |
Tridimensional Analysis Framework
The tridimensional framework, described in a peer-reviewed publication, analyzes neurodegenerative diseases across three fundamental biological axes. Each axis represents a distinct level of pathophysiological organization.
Axis 1: Etiological Factors
Comprehensive genetic risk assessment including pathogenic variants, polygenic risk scores, and environmental modifiers.
Examples: APOE ε4 dosage, LRRK2 G2019S, C9orf72 expansions, MAPT mutations, HTT CAG repeats
Axis 2: Molecular Biomarkers
Multi-omics integration of CSF, plasma, and tissue biomarkers across pathogenic cascades.
Examples: Aβ42/40 ratio, p-tau181/217, α-synuclein RT-QuIC, TDP-43, neurofilament light
Axis 3: Topographical Phenotype
Quantitative neuroimaging analysis and standardized anatomical atrophy mapping.
Examples: Hippocampal volumetry, cortical thickness, white matter integrity, amyloid PET SUVR
Clinical Research Applications
Designed for clinical research environments and pharmaceutical discovery. Supports biomarker validation, drug target verification, and clinical trial stratification.
Biomarker Discovery
- • Multi-omics pathway analysis
- • Cross-disease biomarker validation
- • Longitudinal progression markers
- • Treatment response indicators
Clinical Trial Support
- • Patient stratification algorithms
- • Endpoint sensitivity optimization
- • Statistical power estimation
Drug Development
- • Target engagement verification
- • Disease-modifying therapy tracking
- • Companion biomarker protocols
Structured Analysis Pipeline
Multi-modal data formatting
Significance and FDR correction
Cross-validation and bootstrap
Audit-ready documentation
Advance Neurodegenerative Disease Research with Structured Methods
Built for research institutions and clinical investigators conducting biomarker discovery and clinical trial design.